Healthy adult
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Those who provided specimens in which oligosaccharide increased the number of useful bacteria in vitro 2.Those who belongs to R&D division on the date of consent 3.Those who have received sufficient explanation about the purpose and content of this study, have the consent ability and good understandings, and have agreed voluntarily to participate in the study
Exclusion criteria
Exclusion criteria: 1.Those who have participated in other intervention studies in the month prior to screening or who plan to participate in other intervention studies during the period from screening to the end of the intake period 2.Those who have a history of gastric or lower gastrointestinal tract surgery excluding hemorrhoids 3.Those who have a barium stomach X-ray, small or large intestine endoscopy, or bowel cleansing at a clinic or at home in the month prior to screening or who plan to have these procedures during this study 4.Those who have taken, ingested, or used drugs that may affect the study at least once a week in the month prior to screening, or who plan to take, ingest, or use these drugs at least once during the study 5.Those who plan to travel abroad, travel for more than one week, or go on a business trip during the period from one week prior to the intake period to the end of the intake period 6.Those with lactose intolerance 7.Those with milk allergy 8.Females who are pregnant and/or lactating 9.Those judged as unsuitable for the study by the principal investigator or research physician for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| gut microbiota | — |
Secondary
| Measure | Time frame |
|---|---|
| fecal organic acid concentration, fecal bile acid concentration, blood marker, physical conditions (height, body weight, BMI, muscle mass, body fat mass, body fat percentage, blood pressure), and incidence of adverse events | — |
Countries
Japan
Contacts
Meiji Co., Ltd. R&D Division